|Bid||25.88 x 800|
|Ask||25.92 x 900|
|Day's Range||25.04 - 25.99|
|52 Week Range||11.50 - 65.24|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.50|
Accepted abstracts highlight data from a phase 2 investigator-initiated trial of Rubraca® in pancreatic cancer, clinical and nonclinical research of Rubraca in multiple
BOULDER, Colo.-- -- Exploratory analyses of ARIEL3 Rubraca data in recurrent ovarian cancer presented in oral plenary and poster sessions Maintenance treatment with Rubraca improved median progression-free survival and reduced the risk of progression vs placebo regardless of age subgroup Maintenance treatment with Rubraca significantly improved PFS and reduced the risk of progression vs placebo regardless ...
Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * Bearish sentiment is moderate and declining Bearish sentimentShort interest | NeutralShort interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 26. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CLVS had net inflows of $1.55 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
While it may not be enough for some shareholders, we think it is good to see the Clovis Oncology, Inc. (NASDAQ:CLVS) share price up 29% in a single quarter. ButRead More...
Clovis Oncology, Inc. (CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 11:15 a.m. Eastern time. The conference will be held at the Loews Miami Beach Hotel in Miami. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BOULDER, Colo. & MUNICH-- -- Rubraca ® offers a new monotherapy maintenance treatment option for eligible women with platinum-sensitive relapsed ovarian cancer, regardless of BRCA status Rucaparib provided statistically significant improvement in progression-free survival versus placebo in all ovarian cancer patients studied Some patients with residual disease at ARIEL3 study entry who were treated ...
Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.
AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.
BOULDER, Colo.-- -- 2018 Rubraca ® U.S. sales totaled $95.4M, including $30.4M for the fourth quarter of 2018 Rubraca EU approval granted January 2019 for ovarian cancer maintenance treatment indication; launch in Germany to initiate on this Friday, March 1 Robust Clovis-sponsored Rubraca development program in place; enrollment ongoing for clinical studies in ovarian, prostate and bladder cancers ...
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Clovis Oncology, Inc. (NASDAQ: CLVS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at ...
Clovis Oncology, Inc. (CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern time. The conference will be held at the Lotte New York Palace in New York City. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
DUBLIN and BOULDER, Colo., Feb. 19, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Clovis Oncology, Inc. (CLVS) today announced that the companies have entered into a research collaboration to evaluate ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with rucaparib, Clovis' marketed PARP inhibitor, and lucitanib, Clovis' investigational tyrosine kinase inhibitor. The collaboration will explore the potential anti-cancer effects of both treatment combinations in preclinical models across multiple tumor types.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Clovis Oncology, Inc. will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.S. financial markets.
Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.